According to WHO glaucoma as a cause of blindness is the second among the diseases of the eye. The incidence of vision loss due to glaucoma is 15–20% despite the rapid development of medical and pharmaceutical science.
The ophthalmologist is often necessary to appoint schemes of glaucoma pharmacotherapy that combine multiple medications in the form of eye drops with different mechanisms of action to achieve and maintain a target intraocular pressure (IOP) in patients.
So, the purpose of the work was to study the various aspects of the drugs interaction in the S01E group — Antiglaucoma agents and miotics, which is a key issue of pharmacy and medicine.
Materials and methods. Analysis of secondary sources, including drug register and information-search drugs system compendium, allowing to evaluate the variety and interaction of the active ingredients that make up the mono-drugs and combined antiglaucoma agents.
Results and discussion. The analysis of potential pharmaceutical and pharmacological interactions allowed to find feasible combination: brimonidine with dorzolamide, brinzolamide, timolol and latanoprost, pilocarpine with timolol and betaxolol, acetazolamide, brinzolamide, dorzolamide, timolol, betaxolol, karteolol with latanoprost, bimatoprost with timolol.
Conclusions. Guarantee of the high degree of pharmacotherapy individualization is possible with study of the antiglaucoma drugs combination.
Data on rational, irrational and dangerous combinations of drugs is useful to enhance the effectiveness of glaucoma treatment and prevent the development of side effects.